

References

I-31

1. Flipo R, Mailefert J, Chazeraïn P, et al. Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: Results at 1 year of the ACT-SOLO study. *RMD Open*. 2017;3(1):e000340.
2. Yokota S, Itoh Y, Monio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a realworld clinical setting: Results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. *Ann Rheum Dis*. 2016;75(9):1654-1660.
3. Horneff G, Klein A, Klotsche J, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. *Arthritis Res Ther*. 2016;18: 272.
4. Singh J, Saag K, Bridges L, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2016;68(1):1-26.
5. Czihal, M. Targeting Interleukin-6 in the treatment of giant cell arteritis: Hope or hype? *Vasa*. 2016;45(5):427.
6. Pascart T, Philippe P, Drumez E, et al. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study. *Int J Rheum Dis*. 2016;1093-1102.
7. Micromedex DrugDex Compendium®. 2025. Tocilizumab.
8. Clinical Pharmacology™ Compendium. 2025. Tampa FL: Gold Standard, Inc. Tocilizumab.
9. Roddy JVF, Haverkos BM, McBride A, et al. Tocilizumab for steroid refractory acute graft-versushost disease. *Leukemia & Lymphoma*. 2016;81-85.
10. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. Accessed September 2, 2017.
11. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016. Accessed September 29, 2017.
12. MCGTM Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT:CMT-0009(SR).
13. Kremer JM, Rigby W, Singer NG, et al. Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized, controlled trial. *Arthritis & Rheumatology*. 2018;70(8):1200-1208.
14. Actemra (tocilizumab) injection, for intravenous or subcutaneous use [package insert]. Genentech, Inc. South San Francisco, CA. 09/2024.
15. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. *J Am Acad Dermatol*. 2008;58:826-50.
16. Singh JA, Saag KG, Bridges Jr SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care & Research*. 2015;1-25.
17. Singh JA, Guyatt G, Ogdie A, et al. 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. *J Psoriasis Psoriatic Arthritis*. 2019; 4(1):31-58.

18. Johnson DB, Reynolds KL, Sullivan RJ, et al. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. *The Lancet*. 2020; 21:398-404.
19. [Tocilizumab] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated May 10, 2024.
20. National Comprehensive Cancer Network (NCCN). Tocilizumab. NCCN Drugs and Biologics Compendium®. 2025.
21. Schmitt C, Brockwell L, Giraudon M, et al. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study. *Arthritis Res Ther*. 2022;24(1):133.
22. Tofidence™ (tocilizumab-bavi) injection, for intravenous use. [package insert] Biogen MA Inc., Cambridge MA. Revised 03/2025.
23. Micromedex DrugDex Compendium®. 2025. Tocilizumab-bavi.
24. Tyenne® (tocilizumab-aazg) injection, for intravenous or subcutaneous use. [package insert] Fresenius Kabi USA, LLC., Lake Zurich, IL. Revised 05/2025.
25. Micromedex DrugDex Compendium®. 2025. Tocilizumab-aazg.
26. Avtozma® (tocilizumab-anoh) injection, for intravenous or subcutaneous use. [package insert] Celltrion Inc., Jersey City, NJ. Revised 07/2025.